多靶点分子靶向药的皮肤不良反应与干预措施  

Prevention and intervention for skin adverse effects in multi-target molecular targeted drugs treatment

作　　者：王今[1] 梁琳[1] 杜瀛瀛[2] 

机构地区：[1]安徽医科大学第一附属医院放疗科,合肥230022 [2]安徽医科大学第一附属医院肿瘤科,合肥230022

出　　处：《中国临床保健杂志》2017年第4期449-451,共3页Chinese Journal of Clinical Healthcare

摘　　要：目的观察分析口服多靶点分子靶向药物的肿瘤患者的皮肤不良反应,提出预防和干预措施。方法收集并分析安徽医科大学第一附属医院肿瘤科2006年8月至2017年1月期间,口服索拉非尼、舒尼替尼、阿帕替尼出现皮肤毒性的46例患者的临床资料。结果手足综合征、皮肤干燥、脱屑、斑丘疹、皮肤色素改变、毛发色素减退等是多靶点分子靶向药的常见皮肤不良反应,并针对性进行药物治疗和健康教育。结论早期针对多靶点分子靶向药物的皮肤不良反应进行药物治疗和健康教育,可以改善患者生活质量,提高用药依从性。Objective To observe the skin adverse effects of oral multi-target molecular targeted drugs in tumor patients, and to provide prevention and intervention measures. Methods To collect and analyze the clinical data of 46 patients with skin toxicity of oral sorafenib,sunitinib and apatinib from August 2006 to January 2017 in the First Affilia- ted Hospital of Anhui Medical University. Results Hand-foot syndrome, dry skin, desquamation, rash, skin pigmenta- tion,hair hypopigmentation and so on were common skin adverse reactions of multi-target molecular targeting drugs. Conclusion Importance of early health interventions multi-target molecular targeted skin adverse drug reactions can improve the quality of life of patients and improve medication compliance.

关 键 词：抗肿瘤药/副作用 皮肤表现 分子靶向治疗 毒性作用 

分 类 号：R979.1[医药卫生—药品]